Navigation Links
VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
Date:6/24/2008

ST. JOSEPH, Mich., June 24 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore(TM). VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.

There are 85 researchers and staff members working in VTT's Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology. Further information on VTT: http://www.vtt.fi.

"VTT was our first customer in Finland and an important internationally recognized cancer research center," said Julie Bryant, GeneGo's VP of Business development. "We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT."

About GeneGo, Inc.

GeneGo, Inc. systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
2. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
3. Genencor Appoints New Executive Vice President - Technical Enzymes
4. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
5. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
6. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
7. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
8. Decision Resources, Inc. Acquires Manhattan Research
9. Partnering for Philanthropy Conference Launched to Unite Innovative Non-profit Research Organizations with Philanthropists and Industry
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Stem Cell Researcher Wins Award for Excellence for Work With the ImageStream(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016  With the growing need ... that is underway, therapies such as monoclonal antibodies, ... whole host of indications are in high demand. ... the development and production of these therapeutics. However, ... and high costs, novel approaches and novel expression ...
(Date:2/3/2016)... 2016 New Jersey Health Foundation (NJHF) has ... for researchers in New Jersey ... demonstrates exciting potential.   James M. ... New Jersey Health Foundation Research Grant Program ... institutions— Princeton University, Rutgers University, Rowan University and ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
Breaking Biology Technology:
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
Breaking Biology News(10 mins):